Dedicated to developing global antibody and recombinant protein bio-therapeutics, Hangzhou Just Biotherapeutics, Ltd. (Just China), announced the completion of its Series B funding round.

Located in the Hangzhou Economic & Technological Development Area, Just China's world-class R&D and manufacturing facility will be completed by the end of this year and operational in the first quarter of 2018. Construction and operations of the production center strictly adhere to cGMP standards and will be fully compliant with any country's regulations and guidelines for biopharmaceutical manufacturing.

Globally, Just China has already established clinical development and CMC capabilities with a strong pipeline consisting of both bionovel and biosimilar products. Several leading programs will start to enter clinical stage in 2018.

Just China was founded in February 2016 as a joint venture with Just Biotherapeutics, Inc. (Just), located in Seattle, Washington, USA. As an affiliate, Just China will have access to Just's integrated technology platform, J.DESIGN, and will closely partner with Just to evolve the platform. Applying J.DESIGN technology to molecule, process, product, manufacturing and plant design will enable Just China to develop biologics that meet global quality standards, while accelerating the development process and substantially reducing manufacturing cost.